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(ADCC) have been of increasing interest since their identiﬁcation as a
protective immune correlate in the RV144 clinical vaccine efﬁcacy trial
(Haynes et al., 2012). Earlier studies associated these non-neutralizing
antibodies with protection against HIV infection and disease progres-
sion in both humans and non-human primates (for review see Vargas-
Inchaustegui and Robert-Guroff, 2013). Therefore it is somewhat
surprising to ﬁnd them now linked to HIV pathogenesis. HIV disease
progression is marked by a gradual loss of CD4+ T cells during which
a small proportion of HIV-infected CD4+ T cells and a much larger
proportion of uninfected “bystander” CD4+ T cells are killed. While
numerous mechanisms have been described for infected cell killing,
the mechanism of bystander killing has remained controversial. In this
issue, Richard et al. (2016) attribute bystander killing largely to antibod-
ies mediating ADCC. They further suggest that a small CD4 mimetic
developed by the Sodroski group might be used to alter this pathogenic
mechanism for therapeutic beneﬁt. How can the conﬂicting ﬁndings
regarding ADCC antibodies be explained? And what caveats should be
considered in using CD4 mimetics?
As reported by Richard et al. in this issue of EBioMedicine, the external
envelope of HIV is labile and continually sheds the gp120 component
which then binds the primary viral receptor, CD4, on bystander uninfect-
ed T cells. A subsequent conformational change opens the co-receptor
binding site exposing an epitope recognized by cluster A antibodies, in-
cluding theprototypic ADCC-mediatingmonoclonal antibody, A32. Killing
of the bystander CD4+ T cells follows. Concurrently, the virus subverts
killing of infected cells by down-regulating CD4, inhibiting tetherin, and
internalizing Env (as cited in von Bredow et al., 2015). Consequently,
less Env is expressed on the infected-cell surface, less CD4 is available to
complexwith gp120, and less expression of Env in the open conformation
occurs. Thus ADCC killing of the infected cell is diminished in favor of by-
stander killing.
CD4 mimetics were previously shown to interact with the viral en-
velope, inducing conformational changes, exposing the co-receptor
binding site, and rendering the virus susceptible to neutralization by
CD4-induced antibodies (Madani et al., 2008; Madani et al., 2014). The
Finzi laboratory also previously reported that gp120/CD4 binding with-
in the same infected cell led to exposure of ADCC epitopes (VeilletteDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.12.004.
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that the mimetic decreases binding of shed gp120 to bystander CD4
cells, inferring that less ADCC-mediated killing of these uninfected
cells will result. They also suggest that binding of the mimetic to
envelope remaining on the infected cell surface should “redirect”
ADCC-mediating antibodies to the infected cell away from bystanders,
as stated above. Recent support of this hypothesis showed ADCC killing
of primary HIV-infected T cells was enhanced in vitro by co-culturing
with the CD4 mimetic (Lee et al., 2015).
The current studywas conducted primarilywith the A32 antibody, to-
gether with a small number of sera from HIV-infected individuals. ADCC
antibodies are among the ﬁrst elicited following infection, as the gp120–
CD4 interaction leads to exposure of cluster A epitopes. Not all such
CD4-induced epitopes elicit equivalent ADCC activities, due to subtle dif-
ferences in antibody-epitope recognition and/or Fc differences (Gohain
et al., 2015). Moreover, antibodies targeting other Env sites, including
some with neutralizing activity such as 2G12 and b12, also mediate
ADCC. The relative abundance of all these antibodies in the human sera
tested was not determined. Further, the degree of gp120 shedding and
levels of CD4 and Env present on the cells tested in vitro compared to un-
cultured, primary HIV-infected cells was not reported. It will be critical to
conﬁrm the observations made with in vivo studies using the SHIV
model. Similarly, the in vivo effects of CD4 mimetic administration
must be determined. It is an obvious therapeutic candidate, however,
the possibility that it might facilitate greater CD4-independent infection
must be considered.
Vaccine-elicitedADCC antibodies recognizing cluster A epitopesmight
well be protective, as they target an early epitope uncovered during virus
transmission. Use of the CD4 mimetic in vaccine design might also
stimulate development of such ADCC-mediating antibodies. However, if
incomplete protection and break-through infection occurred following
administration of such a vaccine, accelerated CD4 T cell loss and disease
progression might occur by the mechanism reported by Richard et al..
To circumvent this possibility, vaccine design should include several
immune targets to achieve balanced protection against HIV infection.
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